Biotechnology · Needham, Massachusetts, United States
$9.89
-1.30% (-$0.13)2026-07-09
Smart-Money SignalNeutral · 51/100— Insiders are net sellers over 90 days (-$272K, 2 sales vs 5 buys)
Net Income-$8.9M
EPS$-0.14
Market Cap$724.5M
Price Performance
Historical data including institutional events
Company Profile
P
Paul-Peter Tak
CEO & Executive Director
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops theâ¯enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
- Founded
- 1999
- Employees
- 55
- Headquarters
- Needham, Massachusetts, United States
- Website
- www.candeltx.com
Peer ComparisonRevenue ($B)
▾Loading company sections...